08:31 AM EDT, 05/01/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) reported Q1 non-GAAP earnings Wednesday of $1.20 per diluted share, swinging from a loss of $0.51 a year earlier.

Analysts polled by Capital IQ expected $1.29.

Revenue for the quarter ended March 31 was $515.3 million, up from $420.4 million a year earlier.

Analysts surveyed by Capital IQ expected $512 million.

The biopharmaceutical firm said it ended Q1 with $1.91 billion in cash, cash equivalents, and marketable securities, up from $1.72 billion at the end of last year.

Shares of the company were up 2.5% in recent Wednesday premarket activity.

Price: 141.00, Change: +3.46, Percent Change: +2.52